MAPT and Alzheimer disease: Among the pathophysiological markers of AD [58] include the specific presence of amyloid pathology (decreased Aβ1-42 peptide CSF levels or accumulation of the amyloid tracer in PET imaging) and Tau pathology (elevated Tau and phosphorylated Tau protein CSF levels or accumulation of the Tau tracer in PET imaging).